Alto Neuroscience (ANRO) — My Investment ThesisAlto Neuroscience, Inc.BATS:ANROBigAlex80I currently hold shares of Alto Neuroscience (NYSE: ANRO), which I purchased in October 2026 at approximately $22 per share. Alto is a clinical-stage biotechnology company focused on developing treatments for depression, treatment-resistant depression, and other psychiatric disorders. What attracted me to Alto is its potential to address a major unmet medical need. Many patients suffering from depression do not respond adequately to existing antidepressants. Alto is trying to improve treatment outcomes through its Precision Psychiatry Platform, which uses biological indicators, EEG measurements, and cognitive assessments to help identify which patients may respond best to specific treatments. Why I'm Interested The program I am particularly watching is ALTO-207, which is being developed for treatment-resistant depression. It combines pramipexole, a medication that acts on dopamine receptors and has shown antidepressant potential in previous research, with ondansetron, which is intended to help manage side effects such as nausea. Another important factor is Alto's financial position. As of September 30, 2026, the company reported approximately $319.8 million in cash, with management expecting funding to support planned operations through 2030. This gives it financial flexibility to advance its clinical programs without immediately depending on additional share offerings. Upcoming Catalysts The next six to twelve months could be particularly important: ALTO-300: Phase 2b results expected in the first half of 2027. ALTO-100: Phase 2b results expected around mid-2027. ALTO-207: FDA feedback and Phase 1 formulation results expected by early 2027, with another Phase 3 trial planned. These milestones give Alto several opportunities to demonstrate progress and potentially attract greater investor attention. Risks and My Overall View ANRO remains a high-risk investment. It has no approved commercial products, continues to operate at a loss, and its future depends heavily on clinical trial results. Disappointing results could cause a substantial decline in its share price. However, I believe Alto is worth a closer look because of its pipeline, substantial cash reserves, and upcoming clinical catalysts. Positive results could significantly change how the market values the company. My thesis: I see ANRO as a speculative, high-risk investment with potentially substantial upside. I'm betting on the possibility that its clinical programs deliver meaningful results and that the company can establish itself as a serious player in the psychiatric treatment industry. I'd genuinely like to hear other investors' thoughts on ANRO. Given my approximate $22 entry price, would you continue holding the shares for the upcoming clinical catalysts, or consider taking profits at the current price? I'd also appreciate any bearish perspectives or risks I may have overlooked. Disclaimer: This is my personal investment thesis and not financial advice or a recommendation to buy or sell ANRO. I currently hold shares in the company, purchased in October 2026 at approximately $22 per share, and recognize the significant risks associated with clinical-stage biotechnology investments. Please do your own research before making any investment decisions.